ElexoPharm Receives € 2.1 Million EUROSTARS Grant for Program Targeting Mitochondrial Diseases ("MITOTREAT - E!6654") |
| Print | |
| Monday, 21 May 2012 10:00 (UTC + 2) | ||
Saarbruecken, Germany, May 21, 2012 / B3C newswire / - A EUROSTARS grant of €2.1 million has been awarded to a transnational consortium consisting of During the three years’ grant period, each partner of this multidisciplinary European consortium will contribute its expertise to reach their shared goal. ElexoPharm is responsible for the design and synthesis of small pharmaceutical molecules with state of the art in silico modelling and medicinal chemistry technologies. Khondrion acts as the consortium leader and will carry out the in vitro evaluation of the new chemical entities, including screening in their cell-based mitochondrial disease models. Pharmacelsus is going to perform ADME, toxicity and PK studies in their GLP-certified facilities, and the RUNMC will evaluate the best compounds regarding in vivo efficacy in preclinical studies to achieve Proof of Principle. "ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat these diseases of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, managing director of ElexoPharm.
|
